Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Open Access
- 4 June 2021
- Vol. 13 (11), 2798
- https://doi.org/10.3390/cancers13112798
Abstract
Liquid biopsy is emerging as a promising non-invasive diagnostic tool for malignant pleural effusions (MPE) due to the low sensitivity of conventional pleural fluid (PF) cytological examination and the difficulty to obtain tissue biopsies, which are invasive and require procedural skills. Currently, liquid biopsy is increasingly being used for the detection of driver mutations in circulating tumor DNA (ctDNA) from plasma specimens to guide therapeutic interventions. Notably, malignant PF are richer than plasma in tumor-derived products with potential clinical usefulness, such as ctDNA, micro RNAs (miRNAs) and long non-coding RNAs (lncRNAs), and circulating tumor cells (CTC). Tumor-educated cell types, such as platelets and macrophages, have also been added to this diagnostic armamentarium. Herein, we will present an overview of the role of the preceding biomarkers, collectively known as liquid biopsy, in PF samples, as well as the main technical approaches used for their detection and quantitation, including a proper sample processing. Technical limitations of current platforms and future perspectives in the field will also be addressed. Using PF as liquid biopsy shows promise for use in current practice to facilitate the diagnosis and management of metastatic MPE.Funding Information
- Instituto de Salud Carlos III (PI20-01500, CP20/00039)
- Sociedad Española de Neumología y Cirugía Torácica (678-2018)
- Agència de Gestió d'Ajuts Universitaris i de Recerca (2017SRG1620)
This publication has 133 references indexed in Scilit:
- Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomasBMC Cancer, 2012
- A serum circulating miRNA diagnostic test to identify asymptomatic high‐risk individuals with early stage lung cancerEMBO Molecular Medicine, 2011
- Plasma microRNAs as potential biomarkers for non-small-cell lung cancerLaboratory Investigation, 2011
- Circulating tumor cells: approaches to isolation and characterizationThe Journal of cell biology, 2011
- MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancerProceedings of the National Academy of Sciences of the United States of America, 2011
- Tumour microvesicles contain retrotransposon elements and amplified oncogene sequencesNature Communications, 2011
- Platelets actively sequester angiogenesis regulatorsBlood, 2009
- Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkersNature, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinibBritish Journal of Cancer, 2006